Methods of prognosis and treatment

Patent metadata

Field	Value
Publication number	US-11921119-B2
Application number	US-202017077049-A
Country	US
Kind code	B2
Filing date	Oct 22, 2020
Priority date	Feb 10, 2020
Publication date	Mar 5, 2024
Grant date	Mar 5, 2024

Abstract

A method of determining a management course for treating a subject showing symptoms of a disease is disclosed. The method comprises measuring the TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is above a predetermined amount, the subject is treated as a low-risk patient.

First claim

What is claimed is:

1. A method of determining a management course for a subject who has a diagnosis as having a severe coronaviral infection, comprising:
(a) measuring the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein level in a blood sample of the subject, wherein when the TRAIL level is above 145 pg/ml, the method further comprises:
(b) carrying out a management course selected from the group consisting of: (i) cessation of mechanical ventilation, (ii) cessation of invasive monitoring, (iii) cessation of last-resort drug administration, (iv) cessation of sedation, (v) transfer out of intensive care; and (vi) release from hospital.

2. The method of claim 1 , wherein the management course comprises hospital release.

3. The method of claim 1 , wherein said blood sample is a fraction of whole blood.

4. The method of claim 1 , wherein said blood sample comprises cells selected from the group consisting of lymphocytes, monocytes and granulocytes.

5. The method of claim 3 , wherein said fraction is serum or plasma.

6. The method of claim 1 , wherein said measuring is determined electrophoretically or immunochemically.

7. The method of claim 6 , wherein said immunochemical determination is effected by lateral flow immunoassay, flow cytometry, radioimmunoassay, immunofluorescence or by an enzyme-linked immunosorbent assay.

8. The method of claim 1 , wherein the subject is a child.

9. The method of claim 1 , further comprising measuring the level of Interferon gamma-induced protein 10 (IP10).

10. The method of claim 1 , further comprising measuring the level of at least one determinant selected from the group consisting of: C-reactive protein (CRP), procalcitonin (PCT), IP10, Interleukin 1 receptor type I, Serum amyloid A1, Triggering receptor expressed on myeloid cells 1, Triggering receptor expressed on myeloid cells 2, Radical S-adenosyl methionine domain containing 2, Lipocalin 2, Matrix metallopeptidase 8, MX Dynamin-Like GTPase 1, Calcitonin-related polypeptide alpha, Interleukin 6, 2-amino-6-(1,2,3-trihydroxypropyl)-1H-pteridin-4-one, Interleukin 2, Interleukin 7, and Interleukin 10.

11. The method of claim 10 , wherein said at least one determinant is selected from the group consisting of IP10, procalcitonin (PCT), Interleukin-6 (IL-6) and C-reactive protein (CRP).

12. A method of determining a management course for a subject having a coronaviral infection, comprising:
(a) measuring TRAIL protein level in a blood sample of the subject, wherein when the TRAIL level is below 145 pg/ml, the method further comprises:
(b) carrying out a management course selected from the group consisting of anti-viral treatment, immunomodulatory treatment, mechanical ventilation, invasive monitoring, last-resort drug administration, sedation, intensive care admission, surgical intervention and hospital admittance.

13. The method of claim 12 , further comprising measuring the level of Interferon gamma-induced protein 10 (IP10).

14. The method of claim 12 , further comprising measuring the level of at least one determinant selected from the group consisting of C-reactive protein (CRP), IP10, procalcitonin (PCT), Interleukin 1 receptor type 1, Serum amyloid A1, Triggering receptor expressed on myeloid cells 1, Triggering receptor expressed on myeloid cells 2, Radical S-adenosyl methionine domain containing 2, Lipocalin 2, Matrix metallopeptidase 8, MX Dynamin-Like GTPase 1, Calcitonin-related polypeptide alpha, Interleukin 6, 2-amino-6-(1,2,3-trihydroxypropyl)-1H-pteridin-4-one, Interleukin 2, Interleukin 7, and Interleukin 10.

15. The method of claim 14 , wherein said at least one determinant is selected from the group consisting of IP10, procalcitonin (PCT), Interleukin-6 (IL-6) and C-reactive protein (CRP).

Assignees

• Memed Diagnostics Ltd

Inventors

• Mastboim Niv Steven
• Gottlieb Tanya Michelle
• Oved Kfir
• Eden Eran

Classifications

• G01N33/6863 Primary

  Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors · CPC title

• G01N2333/521

  Chemokines · CPC title

• G01N2333/5412

  IL-6 · CPC title

• G01N2333/585

  Calcitonins · CPC title

• G01N2333/70575

  NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154 · CPC title